13D Filings
LENZ Therapeutics, Inc.
LENZ
Amendment
Ownership

7.00%

Total Shares

1,967,275

Issuer CIK

1815776

CUSIP

52635N103

Event Date

Jun 19, 2025

Accepted

Jun 24, 2025, 04:21 PM

Reporting Persons (9)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Versant Venture Capital VI, L.P.
Partnership
7.00%1,967,2751,967,2750
Versant Ventures VI GP, L.P.
Partnership
7.00%1,967,27501,967,275
Versant Ventures VI GP-GP, LLC
Other
7.00%1,967,27501,967,275
Versant Ventures VII GP-GP, LLC
Other
4.00%1,118,44601,118,446
Versant Venture Capital VII, L.P.
Partnership
4.00%1,118,4461,118,4460
Versant Ventures VII GP, L.P.
Partnership
4.00%1,118,44601,118,446
Versant Vantage II, L.P.
Partnership
3.00%842,162842,1620
Versant Vantage II GP, L.P.
Partnership
3.00%842,1620842,162
Versant Vantage II GP-GP, LLC
Other
3.00%842,1620842,162
Disclosure Items (2)

Security Title

Common Stock, par value $0.00001 per share

Issuer Name

LENZ Therapeutics, Inc.

Issuer Address

201 Lomas Santa Fe Dr., Solana Beach, CA, 92075

Percentage of Class

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Number of Shares

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Transactions

On June 18, 2025, Versant VII sold 100,000 shares of Common Stock at a price per share of $29.95 for aggregate proceeds of approximately $2,995,000.00 On June 20, 2025, Versant VII sold 100,877 shares of Common Stock at a price per share of $30.35 for aggregate proceeds of approximately $3,061,616.95. On June 20, 2025, Versant VI sold 133,924 shares of Common Stock at a price per share of $30.25 for aggregate proceeds of approximately $4,051,201.00.

LENZ Therapeutics, Inc. — Schedule 13D | 13D Filings